PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $835,885 | -51.8% | 50,113 | -20.2% | 0.00% | -50.0% |
| Q2 2023 | $1,735,475 | +98.6% | 62,834 | +65.3% | 0.00% | +100.0% |
| Q1 2023 | $874,023 | +156.5% | 38,001 | +21.7% | 0.00% | – |
| Q4 2022 | $340,796 | +26.2% | 31,237 | -2.5% | 0.00% | – |
| Q3 2022 | $270,000 | +7.6% | 32,032 | +0.7% | 0.00% | – |
| Q2 2022 | $251,000 | -67.8% | 31,815 | -3.3% | 0.00% | -100.0% |
| Q1 2022 | $779,000 | -19.6% | 32,898 | +16.1% | 0.00% | 0.0% |
| Q4 2021 | $969,000 | +97.4% | 28,348 | +2.4% | 0.00% | – |
| Q3 2021 | $491,000 | -60.1% | 27,695 | +0.9% | 0.00% | -100.0% |
| Q2 2021 | $1,231,000 | +124.2% | 27,455 | +29.3% | 0.00% | – |
| Q1 2021 | $549,000 | -46.4% | 21,240 | -58.2% | 0.00% | -100.0% |
| Q4 2020 | $1,025,000 | +90.9% | 50,823 | +85.0% | 0.00% | – |
| Q3 2020 | $537,000 | +50.0% | 27,476 | +62.3% | 0.00% | – |
| Q3 2016 | $358,000 | – | 16,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |